The relationship between the pharmaceutical industry, healthcare professionals (HCPs) and healthcare organisations (HCOs) plays a vital role in the development and delivery medicines. Rosemont Pharmaceuticals follow the ABPI's Code of Practice for the Pharmaceutical Industry and so are required to disclose certain transfers of value, payments and other benefits in kind made to the HCPs & HCOs that we work with.
For more information about the ABPI Disclosure UK, please visit: https://www.abpi.org.uk/our-ethics/disclosure-uk/about-disclosure-uk/
Healthcare Professionals and Organisations
Rosemont discloses its interactions and relevant transfers of value with HCPs & HCOs. This includes the support to HCOs in the form of donations and grants, as well as benefits in kind and sponsorship agreements to manage an event. It also covers the support to HCPs for services and consultancy fees as well as related expenses and contributions to the cost of events.
2020 Rosemont’s interactions and support to HCOs and HCPs
Patient Organisations and the Public including Patients & Journalists
Rosemont has provided financial support to or engaged for contracted services with patient organisations.
2020 Rosemont’s interactions and support to Patient Organisations
